Blood product belongs to biological products and is a biological active preparation which collects healthy blood as the raw material and then is made through biological process or separation and purification technologies. Blood products are irreplaceable in the application of medical emergency and prevention & treatment to some specific diseases.
China blood product industry is about to see a fast and steady growth: due to the increasing population, high incidence rate of malignant disease and growing national economy, blood product market demands are expected to remain growing at 15% annually; China didn’t approve to found new blood product enterprises since 2001, which together with imports limit creates a relatively stable competition environment; after plasma collection stations got restructured, blood product industry chain has become more flexible, which is favor to a long-term development; and industrial supervision will be increasingly strict.
Since the state started regulating plasma collection stations in 2004, plasma volume collected has been sliding, to 3,000 tons in 2005 and 2006. As plasma collection stations finished the restructuring, the plasma volume collected has been gradually increasing but plasma supply still falls short presently. The supply and demand are expected to come to a balance by 2008.
Trend of Plasma Volume Collected in China, 2001-2008
When the restructuring is over, plasma volume collected is ready to still play an important role for the blood product enterprises to get developed but more important is the ability to manage plasma source. Plasma source management is mainly focused on plasma source scale management and plasma source quality control. Plasma source quality is measured by collected volume of featured plasma, plasma donors’ management and guarantee to plasma security.
Plasma price keeps growing steadily even after plasma collection stations are restructured, which is because, on the one hand, plasma supply is gradually coming back but still in short; on the other hand, plasma price is quite transparent and even if the cost is added under the counter, it can be seen on the final price.
China still can’t meet the demands for plasma during 2006-2008 periods; as a result, human serum albumin price will keep high during 2007-2008 periods.
Leading enterprises have fostered strong competitive advantages from upstream—quantity, quality and management of plasma collection stations to downstream products’ R & D, production and distribution. There will form 2-3 nationwide leader and 5-6 regional leaders in China blood product industry in the future while those small weak enterprises will be phased out.
China Animal Vaccine Industry Report, 2019-2025
Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...
China Blood Product Industry Report, 2020-2026
With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...
China Vacuum Blood Collection Device Industry Report, 2019-2025
As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...
China Human Vaccine Industry Report, 2019-2025
China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...
China Independent Clinical Laboratory Industry Report, 2019-2025
China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...
Global and China Monoclonal Antibody Industry Report, 2019-2025
Global monoclonal antibody market can be presented as follows:
1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...
China Contract Research Organization (CRO) Industry Report, 2019-2025
The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...
China Blood Product Industry Report, 2019-2025
With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...
China Human Vaccine Industry Report, 2018-2022
As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination.
The lot release volum...
China Contract Research Organization(CRO) Industry Report, 2017-2021
Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...
China Vacuum Blood Collection Device Industry Report, 2017-2021
China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...
China Independent Clinical Laboratory Industry Report, 2017-2021
China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...
China Human Vaccine Industry Report, 2017-2021
The human vaccine industry presented the following main characteristics in 2016 in China:
1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...
China Independent Clinical Laboratory Industry Report, 2016-2020
Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...
China Human Vaccine Industry Report, 2016-2020
Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...
China Animal Vaccine Industry Report, 2016-2020
Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...
China Blood Product Industry Report, 2016-2019
Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...
China Contract Research Organization (CRO) Industry Report, 2015-2018
In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...